

Invitation
ART Vienna 2024

Advanced Retinal Therapy

Saturday, 7th December 2024
Van Swieten Saal, Medical University of Vienna
Van-Swieten-Gasse 1a, 1090 Vienna

www.meduniwien.ac.at/art-2024

DEPARTMENT OF OPHTHALMOLOGY
AND OPTOMETRY

MEDICAL UNIVERSITY OF VIENNA

Vienna Healthcare Group
University Hospital Vienna

Dear colleagues,

it is a great pleasure and privilege to invite you to the 21st ART Vienna conference on advanced retinal therapy in 2024.
Novel topics have appeared on the horizon of retinal research, both scientifically and clinically – all requiring the sharing of information as well as expert discussion!

Our team has put together three major sessions with the following topics:

- Gene Therapy and Biology
- Geographic Atrophy: Diagnostic Tools
- Geographic Atrophy: Therapeutic Options
- AI-Based Retinal Imaging
- Neovascular AMD in 2024
- Diabetic Macula and Retina

We have invited speakers who are excelling in moving the field forward.
For a lively exchange of ideas and a robust understanding the content face-to-face encounters are essential. This year's conference will provide this most important opportunity for inter-individual exchange. Interactive discussion and debate will be strengthened by panel discussions with the participation of all speakers in small groups related to their comment topic.

With this spirit of advancing the field of retina ahead in a collaborative and person-driven effort, we are very much looking forward to seeing and hearing from you on December 7th, 2024.

Ursula Schmidt-Erfurth
Department of Ophthalmology and Optometry,
MedUni Vienna/University Hospital Vienna, Austria

Online Registration
www.meduniwien.ac.at/art-2024
Please note that your registration will not be valid until your bank transfer has been completed!

Fees should be paid to:
Medical University of Vienna
Reference: KO74600010
Code: ART2024 and "Name of participant"
ERSTE BANK
BIC: GIBAATWW
IBAN: AT36 2011 1404 1007 0700

Onsite Registration
Payment in cash only, no credit cards or debit cards accepted.

Participation Fee
includes scientific programme, lunch and coffee break

Specialist	€ 250
Doctor in training	€ 150

(certificate required, please email to
rebecca.leitner@meduniwien.ac.at
VAT included in the above mentioned rates)

Cancellation Policy
Any cancellation should be made via email:
rebecca.leitner@meduniwien.ac.at

Before November 21st, 2024	no cancellation charge
After November 21st, 2024	50 % registration fee
After November 28th, 2024	no refund

DFP APPROBIERT This event will be approved by the Austrian Medical Chamber with 10 DFP-Points.

Please be aware that photographs and/or video footage will be taken at the event. These may be used for the purpose of documenting or reporting the event and published in print and online media, on various social media platforms and on MedUni Vienna's website.



Van Swieten Saal, Medical University of Vienna
Van-Swieten-Gasse 1a
1090 Vienna

In cooperation with

oertli SWITZERLAND

Apellis

AVICEDA THERAPEUTICS

Boehringer Ingelheim

HEIDELBERG ENGINEERING

Roche

TOPCON Healthcare

Cover: Valery Brozhinsky/Shutterstock.com

Programme

8.00 am
Welcome and Opening
Ursula Schmidt-Erfurth

8.05 – 9.00 am
Session I: Gene Therapy and Biology

The pioneers in RPE65: long-term experiences in gene therapy
Peter Kiraly

Clinical benefit in current gene therapy trials for inherited retinal diseases
Christine Kay

The relevant components of macular fluorescence
Paul S. Bernstein

Consensus classification of geographic atrophy
Glenn J. Jaffe

Efficacy of neurotrophic factors in macular telangiectasis
Paul S. Bernstein

Panel discussion

9:00 – 10.00 am
Session II: Geographic Atrophy: Diagnostic Tools

Learning from "Failed" GA Trials
Nancy M. Holekamp

Human expert vs. AI-based evaluation of GA activity
Gregor Reiter

Photography and/vs. OCT in GA
Amitha Domalpally

Imaging GA biomarkers in the real-world
Ariadne Whitby

Complete and partial loss of the ellipsoid zone as two biomarkers
Justis P. Ehlers

GA and secondary development of macular neovascularization
Dilraj Grewal

Panel discussion

10.00 – 10.30 am
Coffee break

10.30 am – 11.30 pm
Session III: Geographic Atrophy: Therapeutic Options

A comparison of complement inhibitors
Paul Hahn

Pegcetacoplan vs. Avacincaptad Pegol in geographic atrophy: Anchored matching-adjusted indirect comparisons of three phase 3 trials over 24 months
Marco Zarbin

Role of functional outcomes to determine therapeutic benefits in GA treatments
Karl G. Csaky

Targeted and automated assessment of function in GA
Klaudia Birner

State-of-the-art in microperimetry to assess progression and therapeutic benefit in atrophic macular diseases
Maximilian Pfau

Correlation of ellipsoid zone loss and central visual function
Glenn J. Jaffe

Panel discussion

11.30 am – 12:30 pm
Lunch break

12.30 – 1.50 pm
Session IV: AI-Based Retinal Imaging

Keynote: AI regulatory and reimbursement aspects in the US
Michael D. Abramoff

AI-based imaging of the earliest sign in GA
Julia Mai

AI for monitoring disease progression
Jayashree Kalpathy-Cramer

Automated macular disease monitoring in real world management
Ulrich Kellner

From clinical biomarkers to AI-based standards
Amitha Domalpally

Specialist vision-language models for clinical ophthalmology
Martin Menten

Foundation models: State-of-the-art and perspectives in retinal disease
Hrvoje Bogunovic

Panel discussion

1.50 – 2.20 pm
Coffee break

2.20 – 3.40 pm

Session V: Neurovascular AMD in 2024

VEGF and other therapeutic targets in neovascular AMD
Rajendra Apte

Disease activity criteria impact dosing interval assignment in nAMD trials
Marco Zarbin

Benefits and challenges of continuous drug delivery in nAMD
Nancy Holekamp

The elephant in the room: understanding the pathogenesis of AMD
Andrew Lotery

Home OCT-guided treatment versus treat and extend for the management of neovascular AMD: a DRCR retina network protocol
Mathew W. MacCumber

Impact of fluid on functional parameters
Sophie Frank-Publig

VEGF and other therapeutic targets in neovascular AMD
Rajendra Apte

Influence of MNV type on therapeutical outcomes in nAMD
Daniel Barthelmes

Panel discussion

3.40 – 5.00 pm

Session VI: Diabetic Macula and Retina

An overview on pathways and outcomes of DME treatments
Michael Tolentino

From controlled clinical trials to real-world data: Evidence to manage DME
Catherine Creuzot-Garcher

Evolving treatment patterns in DME
Paul Hahn

Angiopoietin inhibition: Real world evidence for enhanced efficiency
Andreas Pollreisz

Symptomatic ERM in eyes with good vision: The DRCR retina network approach
Mathew MacCumber

Autonomous AI for the diabetic eye exam: a paradigm shift in medicine
Michael Abramoff

Panel discussion

5.00 pm
Closing

Speaker

Michael D. Abramoff, University of Iowa, Iowa, USA

Rajendra Apte, School of Medicine, Washington University St. Louis, USA

Daniel Barthelmes, University Hospital Zurich, CH

Paul S. Bernstein, Moran Eye Center, University of Utah, USA

Klaudia Birner, Hrvoje Bogunovic, Sophie Frank-Publig, Julia Mai, Andreas Pollreisz, Gregor Reiter und Ursula Schmidt-Erfurth,
MedUni Vienna/University Hospital Vienna, Austria

Karl G. Czaky, Retina Foundation of the Southwest, Dallas, Texas USA

Catherine Creuzot-Garcher, University Hospital, Dijon, France

Amitha Domalpally, University of Wisconsin, Madison, USA

Justis P. Ehlers, Cleveland Clinic, Ohio, USA

Dilraj Grewal und Glenn J. Jaffe, Department of Ophthalmology, Duke University, Durham, USA

Paul Hahn, NJRetina, USA

Nancy M. Holekamp, Roche Pharmaceuticals

Jayashree Kalpathy-Cramer, University of Colorado Anschutz Medical Campus, USA

Christine Kay, Vitreoretinal Surgery, Vitreoretinal Associates, Gainesville FL, USA

Ulrich Kellner, AugenZentrum Siegburg, Germany

Peter Kiraly, Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford UK

Andrew Lotery, University of Southampton UK

Mathew W. MacCumber, Rush University Medical Center, Illinois Retina Associaties, Chicago, USA

Martin Menten, Technical University of Munich, Germany

Maximilian Pfau, University Hospital Basel, Basel, Switzerland

Michael Tolentino, University of Central Florida, USA

Ariadne Whitby, RetInSight GmbH, Vienna, Austria

Marco Zarbin, Rutgers University, USA

Scientific Management
Ursula Schmidt-Erfurth, Department of Ophthalmology and Optometry, MedUni Vienna/ University Hospital Vienna, Austria
Tel. +43 (0)1 40 400-79410, Fax: -79120
rebecca.leitner@meduniwien.ac.at